Trial Profile
An Extension Study of T-1101 (Tosylate) Administered Orally to Patients With Advanced Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2022
Price :
$35
*
At a glance
- Drugs T 1101 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Taivex Therapeutics
- 14 Apr 2021 Status changed from active, no longer recruiting to completed.
- 09 Mar 2020 Planned End Date changed from 1 Dec 2019 to 31 Dec 2020.
- 09 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 31 Dec 2020.